Astellas Pharma Inc (ALPMF) 14.2300 $ALPMF
Enrollment Surges for Biomanufacturing Training at Worcester Polytechnic Institute
PRWeb - Thu Sep 10, 12:51PM CDT
Enrollment at the Biomanufacturing Education and Training Center (BETC) at Worcester Polytechnic Institute (WPI) more than doubled in the fiscal year that ended June 30, 2015.
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015
M2 - Thu Sep 10, 11:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shtzhn/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - ATLAB Pharma - Altor BioScience - Amgen - Astellas Pharma - AstraZeneca - BIND Therapeutics - Boehringer Ingelheim - Boston Biomedical - Eli Lilly and Company - Exelixis - Incyte Corporation - Johnson & Johnson - Merck & Co. - Mirati Therapeutics - Novartis - Pfizer - Sanofi - Sumitomo Dainippon Pharma - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/sh...ional_cell
JNJ: 92.93 (+0.21), MRK: 52.09 (-0.63), INCY: 131.01 (+6.51), AMGN: 153.21 (+0.07), TEVA: 63.66 (+1.62), LLY: 81.80 (+0.96), BIND: 5.05 (+0.13), MRTX: 43.38 (+8.58), NVS: 96.55 (+0.28)
Vernal Keratoconjunctivitis - Global Clinical Trials Review, H2, 2015
M2 - Thu Sep 10, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dphsww/vernal) has announced the addition of the "Vernal Keratoconjunctivitis Global Clinical Trials Review, H2, 2015" report to their offering. Vernal Keratoconjunctivitis Global Clinical Trials Review, H2, 2015" provides an overview of Vernal Keratoconjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Vernal Keratoconjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Companies Mentioned - Astellas Pharma Inc. - Senju Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Novartis AG - Novagali Pharma SA - Laboratoires Thea S.A. - Funds for Research in Ophthalmology - Chiltern International Limited - Ajanta Pharma Limited For more information visit http://www.researchandmarkets.com/research/dphsww/vernal
NVS: 96.55 (+0.28)
Thrombosis - Pipeline Review, H1 2015
M2 - Thu Sep 10, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4rbgj/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Archemix - Arena Pharmaceuticals - Armetheon. - Arrowhead Research - Astellas Pharma - AstraZeneca - Bayer - Bristol-Myers Squibb Company - Cardax Pharmaceuticals - Cereno Scientific - China Biologic Products - CSL - Daewoong Pharmaceutical - Daiichi Sankyo - Eisai - F. Hoffmann-La Roche - Gamma Therapeutics - Generex Biotechnology - GlycoMimetics - Green Cross - IMMD - Isis Pharmaceuticals - Johnson & Johnson - Laboratorios Farmaceuticos Rovi - LG Life Sciences - Lipicard Technologies - Merrion Pharmaceuticals - Nostrum Pharmaceuticals - Pfizer - PLx Pharma - Portola Pharmaceuticals - Prothix BV - Sagene Pharmaceuticals - Sanofi - SciFluor Life Sciences - Tobira Therapeutics. - Zedira For more information visit http://www.researchandmarkets.com/research/m4rbgj/thrombosis
CBPO: 99.84 (+1.16), JNJ: 92.93 (+0.21), PTLA: 49.77 (+3.03), ISIS: 54.08 (+1.07), BMY: 59.22 (+0.47), TBRA: 13.18 (+0.20), ARNA: 2.86 (+0.15)
Global Constipation Pipeline Review 2015 - 16 Companies & 18 Drug Profiles
M2 - Tue Sep 08, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b5h9s9/constipation) has announced the addition of the "Constipation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Ardelyx, Inc. - Astellas Pharma Inc. - Braintree Laboratories, Inc. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Ironwood Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - RaQualia Pharma Inc. - Rhythm Pharmaceuticals - Sanwa Kagaku Kenkyusho Co., Ltd. - Shire Plc - SK Biopharmaceuticals Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. Drug Profiles - ASP-7663 - BLI-400 - DA-6886 - DS-3801 - DSP-6952 - elobixibat - KWA-0711 - linaclotide - lubiprostone - plecanatide - prucalopride succinate - relamorelin - relenopride hydrochloride - RQ-00000010 - SK-1202 - Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia - tenapanor hydrochloride - Transilon For more information visit http://www.researchandmarkets.com/research/b5...nstipation
SGYP: 7.24 (+0.12), IRWD: 11.62 (+0.50), SHPG: 223.00 (-2.43), SCMP: 25.30 (+0.49)
High Triglyceridemia - Pipeline Review, H2 2015
M2 - Tue Sep 08, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k6prfz/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - BASF SE - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Essentialis, Inc. - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Michigan Life Therapeutics, LLC - Novartis AG - Pharmena SA - Tekmira Pharmaceuticals Corp. - Thetis Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/k6prfz/high
AGN: 295.24 (+1.64), ACST: 0.32 (unch), ISIS: 54.08 (+1.07), AZN: 33.30 (+0.02), TKMR: 10.83 (+0.58), CBAY: 2.80 (+0.07), NVS: 96.55 (+0.28)
Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015
M2 - Fri Sep 04, 3:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6hqs3/diabetic) has announced the addition of the "Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Acorda Therapeutics - Astellas Pharma - Cebix - Pfizer - ViroMed For more information visit http://www.researchandmarkets.com/research/h6hqs3/diabetic
ACOR: 33.07 (+0.14)
China Tamsulosin Market Investigation Report 2010-2019
M2 - Thu Sep 03, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgb9fs/investigation) has announced the addition of the "Investigation Report on China Tamsulosin Market, 2010-2019" report to their offering. Compared with other a1- adrenergic receptor blockers, tamsulosin hydrochloride developed by Yamanouchi enjoys higher selectivity and lower risk of urinary tract infections and therefore is fitter for BPH treatment. Ever since its debut in 1993 in Japan, tamsulosin hydrochloride has been sold in various brands in 64 countries according to Yamanouchi's authorization to Boehringer Ingelheim. Prostate drug market is highly concentrated in China. Three kinds of prostate drugs - finasteride, tamsulosin and prostat which occupy over 90% of prostate drug market altogether, reported over 10 million sales in sample hospitals in 2005. Tamsulosin develops rapidly after entering China with annual sales less than CNY 50 million in 2005 rising to CNY 201 million in 2014 and CAGR reaching 16.98% during this period. Tamsulosin enjoys a vast market demand in China and products made by Zhejiang Hailisheng Pharmaceutical Co., Ltd, Jiangsu Heng Rui Medicine Co., Ltd, Astellas Pharma Inc, Yamanouchi Pharmaceutical Co., Ltd and Kunming Jida Pharmaceutical Co., Ltd have taken up a large share of the market. With the aging of the population in China, the incidence of BPH and its number of cases will keep going up. The market size of tamsulosin in China is expected to keep expanding in the next few years. Key Topics Covered: 1 Related Concepts of Tamsulosin 2 Market Profile of Tamsulosin in China 3 Survey on Sales Status of Tamsulosin in China, 2010-2014 4 Survey on Market Share of Major Manufacturers of Tamsulosin in China, 2010-2014 5 Survey on Dosage Forms of Tamsulosin in China, 2010-2014 6 Reference Price of Tamsulosin in Chinese Hospitals in 2014 7 Major Manufacturers of Tamsulosin in Chinese Market, 2010-2014 8 Market Outlook of Tamsulosin in China, 2015-2019 Companies Mentioned - Zhejiang Hailisheng Pharmaceutical Co., Ltd - Jiangsu Heng Rui Medicine Co., Ltd - Kunming Jida Pharmaceutical Co., Ltd - Yamanouchi Pharmaceutical Co., Ltd - Astellas Pharma Inc For more information visit http://www.researchandmarkets.com/research/jg...estigation
Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015 - Marketed Histone Deacetylase (HDAC) Inhibitor Clinical Insight by Company & Indication
M2 - Wed Aug 19, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r7q5t4/histone) has announced the addition of the "Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015" report to their offering. Histone Deacetylase (HDAC) are enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone. They are responsible for gene expression and regulation which is responsible for cellular functioning. It also helps in wrapping of histone over the Deoxyribonucleic acid (DNA). They are involved in cell growth and death which is responsible for maintaining steady state. Their involvement in diseases has been noted by investigators due to which they could serve as lead molecule for drug development. Development of HDAC based therapeutics is correlated to the development of HDAC inhibitors which have capacity to inhibit HDACs which have gone under abnormal changes. Some of the HDAC inhibitors has been successfully commercialized in global market for different ailments. Potential of HDAC inhibitors in animal models for inflammatory bowel diseases, diabetes, multiple sclerosis, age related macular degeneration, cardiovascular diseases and other diseases have been shown. HDAC inhibitors clinical pipeline is becoming strong as investment in their research and development is increasing. Various products are at different stages of clinical trials which would be introduced in coming years. Key Topics Covered: 1. Introduction to Histone Deacetylase (HDAC) Inhibitors 2. Classification of Histone Deacetylase (HDAC) 3. Classification of Histone Deacetylase (HDAC) Inhibitors 4. Mechanism of Histone Deacetylase (HDAC) Inhibitors 5. Global Histone Deacetylase (HDAC) Inhibitor Market Outlook 6. Histone Deacetylase (HDAC) Inhibitors Market Dynamics 7. Histone Deacetylase (HDAC) Inhibitors Future Prospects 8. Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline by Company, Indication & Phase 9. Marketed Histone Deacetylase (HDAC) Inhibitor Clinical Insight by Company & Indication 10. Discontinued & Suspended Histone Deacetylase (HDAC) Inhibitor Clinical Insight 11. Competitive Landscape Companies Mentioned - 4SC - Acetylon Pharmaceuticals - Astellas Pharma - Celleron Therapeutics - Chipscreen Biosciences - Chong Kun Dang Pharmaceutical - Chroma Therapeutics - CrystalGenomics - Curis - Digna Biotech - Evgen - Italfarmaco - Johnson & Johnson Pharmaceutical Research and Development - MEI Pharma - Mirati Therapeutics - Novartis - Onxeo - Orchid Chemicals and Pharmaceuticals - Pharmacyclics - Repligen - TetraLogic Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r7q5t4/histone
RGEN: 36.49 (+0.96), JNJ: 92.93 (+0.21), MRTX: 43.38 (+8.58), NVS: 96.55 (+0.28), MEIP: 1.86 (+0.02)
Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 33.07 (+0.14), CVD: 106.42 (-0.71), JNJ: 92.93 (+0.21), ABBV: 59.35 (-0.23), ABT: 43.41 (+0.29), CBSTZ: 0.06 (unch), IMGN: 13.86 (+0.59), AMGN: 153.21 (+0.07), BMY: 59.22 (+0.47), GRFS: 32.15 (+0.40), GILD: 109.63 (+2.38), BAX: 36.02 (-0.05), AZN: 33.30 (+0.02), MRK: 52.09 (-0.63), NVS: 96.55 (+0.28), CELGZ: 1.93 (+0.07)
Osteoporosis Pipeline Review, H1 2015 - Reviews key players involved in the therapeutics development for Osteoporosis
M2 - Mon Aug 17, 8:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7r4gzx/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoporosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Abiogen Pharma S.p.A. - Ablynx NV - Alethia Biotherapeutics Inc. - Alize Pharma SAS - Alkem Laboratories Ltd. - Amgen Inc. - Amura Holdings Limited - Arcarios BV - Astellas Pharma Inc. - Bone Medical Limited - Bone Therapeutics SA - Caladrius Biosciences, Inc. - Chronos Therapeutics Limited - Chugai Pharmaceutical Co., Ltd. - Corium International, Inc. - Critical Pharmaceuticals Limited - Daiichi Sankyo Company, Limited - ElexoPharm GmbH - Eli Lilly and Company - EndoCeutics, Inc. - Ensoltek Co., Ltd. - Enzo Biochem, Inc. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Glide Pharmaceutical Technologies Limited - Hanmi Pharmaceuticals, Co. Ltd. - Haoma Medica Ltd. - IMMD Inc. - Immunovo BV - Inbiopro Solutions Pvt. Ltd. - Kaken Pharmaceutical Co., Ltd. - Kolltan Pharmaceuticals, Inc. - Lead Discovery Center GmbH For more information visit http://www.researchandmarkets.com/research/7r...teoporosis
AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), CLBS: 1.97 (+0.01), GLPG: 59.00 (-0.06), CORI: 10.76 (+0.06), ENZ: 3.04 (-0.03)
Global Streptococcal Infections Active Pharmaceutical Ingredients (API) Insights 2015-2016
M2 - Mon Aug 17, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nzsv6x/streptococcal) has announced the addition of the "Streptococcal Infections-API Insights" report to their offering. Streptococcal Infections-API Insights, 2015 report provides Streptococcal Infections drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Streptococcal Infections. The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Streptococcal Infections drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2012-2016) - Marketed Drugs Information - Drugs Description - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Discontinued Drugs Information Companies Mentioned - Hospira, Inc. - Arbor Pharmaceuticals, Inc. - Pfizer Inc. - Abbott Laboratories - Astellas Pharma US, Inc. - Pharmacia & Upjohn, Inc. - Warner Chilcott Plc - Baxter Healthcare Corporation For more information visit http://www.researchandmarkets.com/research/nz...eptococcal
ABT: 43.41 (+0.29), PFE: 32.97 (+0.35)
Ovarian Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Ovarian Cancer
M2 - Mon Aug 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/752ksw/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. Summary This, Ovarian Cancer - Pipeline Review, H1 2015', provides an overview of the Ovarian Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: Overview Therapeutics Development Therapeutics under Development by Companies Therapeutics under Investigation by Universities/Institutes Pipeline Products Glance Products under Development by Companies Products under Investigation by Universities/Institutes Companies Involved in Therapeutics Development Therapeutics Assessment Drug Profiles Recent Pipeline Updates Dormant Projects Discontinued Products Product Development Milestones Companies Mentioned - 3-V Biosciences, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abeona Therapeutics, Inc. - AbGenomics International, Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advantagene, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Agilvax, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Amorfix Life Sciences Ltd. - Anavex Life Sciences Corp. - Angstrom Pharmaceuticals, Inc. - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aprea AB - arGEN-X BV - Armour Therapeutics Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. For more information visit http://www.researchandmarkets.com/research/75...ian_cancer
ADXS: 16.51 (+0.55), ADRO: 20.40 (+0.27), AMBX: (), AMGN: 153.21 (+0.07), ABEO: 5.48 (+0.17), AAAP: (), ABBV: 59.35 (-0.23), PMN.TO: 0.07 (-0.02), ARRY: 5.88 (-0.05), XLRN: 33.62 (+1.44)
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 - Summarizes all the dormant and discontinued pipeline projects
M2 - Mon Aug 17, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q7drg7/glioblastoma) has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. Summary This, Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AB Science - AbbVie Inc. - Actelion Ltd - Actinium Pharmaceuticals, Inc. - Actinogen Limited - Activartis Biotech GmbH - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advanced Cancer Therapeutics - Advenchen Laboratories, LLC - Agenus, Inc. - AGY Therapeutics, Inc. - Amal Therapeutics SA - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AngioChem Inc. - Apogenix GmbH - Argon Pharma S.L. - Ariad Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Axelar AB - Bexion Pharmaceuticals, LLC. - biOasis Technologies Inc. - BioCancell Ltd - Biomar Microbial Technologies - Bioncotech Therapeutics S.L. - Biovista Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q7...ioblastoma
ATNM: 2.44 (+0.07), ADRO: 20.40 (+0.27), AMBX: (), AZN: 33.30 (+0.02), AMGN: 153.21 (+0.07), AMPE: 3.12 (+0.14), ABBV: 59.35 (-0.23), BMY: 59.22 (+0.47), AAAP: ()
Colorectal Cancer - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colorectal Cancer
M2 - Fri Aug 14, 5:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvsdxp/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Key Topics Covered: - Colorectal Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Angiogene Pharmaceuticals Limited - Antibe Therapeutics, Inc. - Aphios Corporation - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Bayer AG - Beta Cat Pharmaceuticals, LLC - Biocon Limited - Bionomics Limited - BioNovion B.V. - Biothera, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company For more information visit http://www.researchandmarkets.com/research/dv...tal_cancer
ADXS: 16.51 (+0.55), ARQL: 1.71 (-0.01), AMGN: 153.21 (+0.07), BMY: 59.22 (+0.47), ATNM: 2.44 (+0.07), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), ABBV: 59.35 (-0.23), ARRY: 5.88 (-0.05)
Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Multiple Myeloma (Kahler's Disease)
M2 - Fri Aug 14, 5:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjk4fl/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015" report to their offering. This, Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015', provides an overview of the Multiple Myeloma (Kahler's Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler's Disease) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Key Topics Covered: - Multiple Myeloma (Kahler's Disease) Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - 4SC AG - AB Science - AbbVie Inc. - Ablynx NV - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Actinium Pharmaceuticals, Inc. - Adaptimmune Limited - Advancell - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Amorfix Life Sciences Ltd. - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Aptose Biosciences Inc. - Arcarios BV - Arno Therapeutics, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Aurigene Discovery Technologies Limited - AVEO Pharmaceuticals, Inc. - AvidBiotics Corp. - Axelar AB - Bayer AG - BenovusBio LLC - Biogenomics Limited - BioInvent International AB - BioNovion B.V. - Biotest AG - Bluebird bio, Inc. For more information visit http://www.researchandmarkets.com/research/rj...le_myeloma
AMGN: 153.21 (+0.07), APTO: 5.05 (-0.02), ATNM: 2.44 (+0.07), ANTH: 8.03 (-0.15), AVEO: 1.36 (unch), ABBV: 59.35 (-0.23), PMN.TO: 0.07 (-0.02), XLRN: 33.62 (+1.44), ARRY: 5.88 (-0.05)
Schizophrenia - Pipeline Review, H1 2015
M2 - Fri Aug 14, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fjzmkc/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 70 companies featured in the report: - Acadia Pharmaceuticals - Adamed Sp. - Aestus Therapeutics - AGY Therapeutics - Alkermes - Amgen - Angita - ANP Technologies - Ascendis Pharma - Astellas Pharma - Athersys - BCWorld Pharm - BioCrea - Biotie Therapies - Boehringer Ingelheim - Cerecor - Critical Pharmaceuticals - Curemark - Delpor - Domain Therapeutics - Dong Wha Pharma - Echo Pharmaceuticals - Egis Gyogyszergyar Nyrt - Eli Lilly and Company - Evotec - F. Hoffmann-La Roche - FORUM Pharmaceuticals - Galenea - GeNeuro - Genovate Biotechnology Full list available at http://www.researchandmarkets.com/research/fj...izophrenia
ACAD: 41.69 (+0.52), AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), ALKS: 70.95 (+1.28)
Hepatic Insufficiency Global Clinical Trials Review, H1 2015 - Clinical Trial Overview of Top Companies
M2 - Thu Aug 13, 6:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/927w44/hepatic) has announced the addition of the "Hepatic Insufficiency Global Clinical Trials Review, H1, 2015" report to their offering. Hepatic Insufficiency Global Clinical Trials Review, H1, 2015 Summary Our clinical trial report, Hepatic Insufficiency Global Clinical Trials Review, H1, 2015" provides data on the Hepatic Insufficiency clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatic Insufficiency. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatic Insufficiency. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Merck & Co., Inc. - Novartis AG - Eli Lilly and Company - Puma Biotechnology, Inc. - Johnson & Johnson - GlaxoSmithKline plc - C. H. Boehringer Sohn AG & Co. KG - Pfizer Inc. - Bristol-Myers Squibb Company - Astellas Pharma Europe Ltd. Clinical Trial Overview of Top Institutes / Government - Copenhagen University Hospital Gentofte - Clinical Trial Overview of Copenhagen University Hospital Gentofte - National Cancer Institute - Clinical Trial Overview of National Cancer Institute - Aarhus University - Clinical Trial Overview of Aarhus University - Donau-Universitat Krems - Clinical Trial Overview of Donau-Universitat Krems - Huashan Hospital - Clinical Trial Overview of Huashan Hospital - Mayo Clinic - Clinical Trial Overview of Mayo Clinic - McGill University Health Center For more information visit http://www.researchandmarkets.com/research/927w44/hepatic
JNJ: 92.93 (+0.21), PFE: 32.97 (+0.35), MRK: 52.09 (-0.63), LLY: 81.80 (+0.96), GSK: 40.26 (+0.02), BMY: 59.22 (+0.47), PBYI: 103.28 (+6.59), NVS: 96.55 (+0.28)
Respiratory Syncytial Virus (RSV) Infections: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fswgvd/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects Companies Mentioned - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AlphaVax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Artificial Cell Technologies, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Celltrion, Inc. - Codagenix, Inc. - Crucell N.V. - CureVac GmbH - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Humabs BioMed SA - iBio, Inc. - Immunovaccine, Inc. - Johnson & Johnson - Kineta, Inc. - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - Microbiotix, Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation For more information visit http://www.researchandmarkets.com/research/fs...espiratory
ADMA: 9.35 (+0.36), EBS: 32.58 (+0.39), BOTA: 2.08 (-0.08), GSK: 40.26 (+0.02), JNJ: 92.93 (+0.21), GILD: 109.63 (+2.38), MRK: 52.09 (-0.63), AZN: 33.30 (+0.02), IBIO: 0.70 (-0.01)
Diffuse Large B-Cell Lymphoma Pipeline Review, H1 2015 - Provides a Snapshot of the Global Therapeutic Landscape of Diffuse Large B-Cell Lymphoma
M2 - Thu Aug 13, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/drv9fj/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Companies Mentioned - AbbVie Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BIND Therapeutics, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - CureTech Ltd. - Curis, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/dr...fuse_large
CRIS: 2.64 (-0.05), EPZM: 20.70 (+0.23), CTIC: 1.62 (+0.01), JNJ: 92.93 (+0.21), INFI: 8.82 (-0.05), ABBV: 59.35 (-0.23), CBMG: 22.85 (-0.01), IMMU: 2.22 (+0.01), INCY: 131.01 (+6.51), IMGN: 13.86 (+0.59), AMGN: 153.21 (+0.07), BIND: 5.05 (+0.13), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), IDRA: 3.34 (+0.26), GILD: 109.63 (+2.38), AZN: 33.30 (+0.02), CELGZ: 1.93 (+0.07)
Enrollment Surges for Biomanufacturing Training at Worcester Polytechnic Institute
PRWeb - Thu Sep 10, 12:51PM CDT
Enrollment at the Biomanufacturing Education and Training Center (BETC) at Worcester Polytechnic Institute (WPI) more than doubled in the fiscal year that ended June 30, 2015.
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015
M2 - Thu Sep 10, 11:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shtzhn/transitional_cell) has announced the addition of the "Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - ATLAB Pharma - Altor BioScience - Amgen - Astellas Pharma - AstraZeneca - BIND Therapeutics - Boehringer Ingelheim - Boston Biomedical - Eli Lilly and Company - Exelixis - Incyte Corporation - Johnson & Johnson - Merck & Co. - Mirati Therapeutics - Novartis - Pfizer - Sanofi - Sumitomo Dainippon Pharma - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/sh...ional_cell
JNJ: 92.93 (+0.21), MRK: 52.09 (-0.63), INCY: 131.01 (+6.51), AMGN: 153.21 (+0.07), TEVA: 63.66 (+1.62), LLY: 81.80 (+0.96), BIND: 5.05 (+0.13), MRTX: 43.38 (+8.58), NVS: 96.55 (+0.28)
Vernal Keratoconjunctivitis - Global Clinical Trials Review, H2, 2015
M2 - Thu Sep 10, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dphsww/vernal) has announced the addition of the "Vernal Keratoconjunctivitis Global Clinical Trials Review, H2, 2015" report to their offering. Vernal Keratoconjunctivitis Global Clinical Trials Review, H2, 2015" provides an overview of Vernal Keratoconjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Vernal Keratoconjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Companies Mentioned - Astellas Pharma Inc. - Senju Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Novartis AG - Novagali Pharma SA - Laboratoires Thea S.A. - Funds for Research in Ophthalmology - Chiltern International Limited - Ajanta Pharma Limited For more information visit http://www.researchandmarkets.com/research/dphsww/vernal
NVS: 96.55 (+0.28)
Thrombosis - Pipeline Review, H1 2015
M2 - Thu Sep 10, 4:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4rbgj/thrombosis) has announced the addition of the "Thrombosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Archemix - Arena Pharmaceuticals - Armetheon. - Arrowhead Research - Astellas Pharma - AstraZeneca - Bayer - Bristol-Myers Squibb Company - Cardax Pharmaceuticals - Cereno Scientific - China Biologic Products - CSL - Daewoong Pharmaceutical - Daiichi Sankyo - Eisai - F. Hoffmann-La Roche - Gamma Therapeutics - Generex Biotechnology - GlycoMimetics - Green Cross - IMMD - Isis Pharmaceuticals - Johnson & Johnson - Laboratorios Farmaceuticos Rovi - LG Life Sciences - Lipicard Technologies - Merrion Pharmaceuticals - Nostrum Pharmaceuticals - Pfizer - PLx Pharma - Portola Pharmaceuticals - Prothix BV - Sagene Pharmaceuticals - Sanofi - SciFluor Life Sciences - Tobira Therapeutics. - Zedira For more information visit http://www.researchandmarkets.com/research/m4rbgj/thrombosis
CBPO: 99.84 (+1.16), JNJ: 92.93 (+0.21), PTLA: 49.77 (+3.03), ISIS: 54.08 (+1.07), BMY: 59.22 (+0.47), TBRA: 13.18 (+0.20), ARNA: 2.86 (+0.15)
Global Constipation Pipeline Review 2015 - 16 Companies & 18 Drug Profiles
M2 - Tue Sep 08, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b5h9s9/constipation) has announced the addition of the "Constipation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Ardelyx, Inc. - Astellas Pharma Inc. - Braintree Laboratories, Inc. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Ironwood Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - RaQualia Pharma Inc. - Rhythm Pharmaceuticals - Sanwa Kagaku Kenkyusho Co., Ltd. - Shire Plc - SK Biopharmaceuticals Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. Drug Profiles - ASP-7663 - BLI-400 - DA-6886 - DS-3801 - DSP-6952 - elobixibat - KWA-0711 - linaclotide - lubiprostone - plecanatide - prucalopride succinate - relamorelin - relenopride hydrochloride - RQ-00000010 - SK-1202 - Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia - tenapanor hydrochloride - Transilon For more information visit http://www.researchandmarkets.com/research/b5...nstipation
SGYP: 7.24 (+0.12), IRWD: 11.62 (+0.50), SHPG: 223.00 (-2.43), SCMP: 25.30 (+0.49)
High Triglyceridemia - Pipeline Review, H2 2015
M2 - Tue Sep 08, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k6prfz/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acasti Pharma Inc. - Allergan Plc - Alnylam Pharmaceuticals, Inc. - Arisaph Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - BASF SE - Cardax Pharmaceuticals, Inc. - Catabasis Pharmaceuticals, Inc. - CymaBay Therapeutics, Inc. - Daiichi Sankyo Company, Limited - Essentialis, Inc. - Isis Pharmaceuticals, Inc. - Jeil Pharmaceutical Co., Ltd. - Michigan Life Therapeutics, LLC - Novartis AG - Pharmena SA - Tekmira Pharmaceuticals Corp. - Thetis Pharmaceuticals LLC For more information visit http://www.researchandmarkets.com/research/k6prfz/high
AGN: 295.24 (+1.64), ACST: 0.32 (unch), ISIS: 54.08 (+1.07), AZN: 33.30 (+0.02), TKMR: 10.83 (+0.58), CBAY: 2.80 (+0.07), NVS: 96.55 (+0.28)
Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015
M2 - Fri Sep 04, 3:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h6hqs3/diabetic) has announced the addition of the "Diabetic Peripheral Neuropathy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to Buy The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Acorda Therapeutics - Astellas Pharma - Cebix - Pfizer - ViroMed For more information visit http://www.researchandmarkets.com/research/h6hqs3/diabetic
ACOR: 33.07 (+0.14)
China Tamsulosin Market Investigation Report 2010-2019
M2 - Thu Sep 03, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgb9fs/investigation) has announced the addition of the "Investigation Report on China Tamsulosin Market, 2010-2019" report to their offering. Compared with other a1- adrenergic receptor blockers, tamsulosin hydrochloride developed by Yamanouchi enjoys higher selectivity and lower risk of urinary tract infections and therefore is fitter for BPH treatment. Ever since its debut in 1993 in Japan, tamsulosin hydrochloride has been sold in various brands in 64 countries according to Yamanouchi's authorization to Boehringer Ingelheim. Prostate drug market is highly concentrated in China. Three kinds of prostate drugs - finasteride, tamsulosin and prostat which occupy over 90% of prostate drug market altogether, reported over 10 million sales in sample hospitals in 2005. Tamsulosin develops rapidly after entering China with annual sales less than CNY 50 million in 2005 rising to CNY 201 million in 2014 and CAGR reaching 16.98% during this period. Tamsulosin enjoys a vast market demand in China and products made by Zhejiang Hailisheng Pharmaceutical Co., Ltd, Jiangsu Heng Rui Medicine Co., Ltd, Astellas Pharma Inc, Yamanouchi Pharmaceutical Co., Ltd and Kunming Jida Pharmaceutical Co., Ltd have taken up a large share of the market. With the aging of the population in China, the incidence of BPH and its number of cases will keep going up. The market size of tamsulosin in China is expected to keep expanding in the next few years. Key Topics Covered: 1 Related Concepts of Tamsulosin 2 Market Profile of Tamsulosin in China 3 Survey on Sales Status of Tamsulosin in China, 2010-2014 4 Survey on Market Share of Major Manufacturers of Tamsulosin in China, 2010-2014 5 Survey on Dosage Forms of Tamsulosin in China, 2010-2014 6 Reference Price of Tamsulosin in Chinese Hospitals in 2014 7 Major Manufacturers of Tamsulosin in Chinese Market, 2010-2014 8 Market Outlook of Tamsulosin in China, 2015-2019 Companies Mentioned - Zhejiang Hailisheng Pharmaceutical Co., Ltd - Jiangsu Heng Rui Medicine Co., Ltd - Kunming Jida Pharmaceutical Co., Ltd - Yamanouchi Pharmaceutical Co., Ltd - Astellas Pharma Inc For more information visit http://www.researchandmarkets.com/research/jg...estigation
Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015 - Marketed Histone Deacetylase (HDAC) Inhibitor Clinical Insight by Company & Indication
M2 - Wed Aug 19, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r7q5t4/histone) has announced the addition of the "Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015" report to their offering. Histone Deacetylase (HDAC) are enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone. They are responsible for gene expression and regulation which is responsible for cellular functioning. It also helps in wrapping of histone over the Deoxyribonucleic acid (DNA). They are involved in cell growth and death which is responsible for maintaining steady state. Their involvement in diseases has been noted by investigators due to which they could serve as lead molecule for drug development. Development of HDAC based therapeutics is correlated to the development of HDAC inhibitors which have capacity to inhibit HDACs which have gone under abnormal changes. Some of the HDAC inhibitors has been successfully commercialized in global market for different ailments. Potential of HDAC inhibitors in animal models for inflammatory bowel diseases, diabetes, multiple sclerosis, age related macular degeneration, cardiovascular diseases and other diseases have been shown. HDAC inhibitors clinical pipeline is becoming strong as investment in their research and development is increasing. Various products are at different stages of clinical trials which would be introduced in coming years. Key Topics Covered: 1. Introduction to Histone Deacetylase (HDAC) Inhibitors 2. Classification of Histone Deacetylase (HDAC) 3. Classification of Histone Deacetylase (HDAC) Inhibitors 4. Mechanism of Histone Deacetylase (HDAC) Inhibitors 5. Global Histone Deacetylase (HDAC) Inhibitor Market Outlook 6. Histone Deacetylase (HDAC) Inhibitors Market Dynamics 7. Histone Deacetylase (HDAC) Inhibitors Future Prospects 8. Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline by Company, Indication & Phase 9. Marketed Histone Deacetylase (HDAC) Inhibitor Clinical Insight by Company & Indication 10. Discontinued & Suspended Histone Deacetylase (HDAC) Inhibitor Clinical Insight 11. Competitive Landscape Companies Mentioned - 4SC - Acetylon Pharmaceuticals - Astellas Pharma - Celleron Therapeutics - Chipscreen Biosciences - Chong Kun Dang Pharmaceutical - Chroma Therapeutics - CrystalGenomics - Curis - Digna Biotech - Evgen - Italfarmaco - Johnson & Johnson Pharmaceutical Research and Development - MEI Pharma - Mirati Therapeutics - Novartis - Onxeo - Orchid Chemicals and Pharmaceuticals - Pharmacyclics - Repligen - TetraLogic Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/r7q5t4/histone
RGEN: 36.49 (+0.96), JNJ: 92.93 (+0.21), MRTX: 43.38 (+8.58), NVS: 96.55 (+0.28), MEIP: 1.86 (+0.02)
Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of nearly 60%
M2 - Tue Aug 18, 2:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6ddnn/analyzing_the) has announced the addition of the "Analyzing the Global Biotechnology Industry 2015" report to their offering. Biotechnology as an industry has been around for many years now. The manipulation of biological processes is nothing new as the fermenting of grains and fruits to create alcoholic beverages to the discovery of penicillin has been around since the 1920s. Advances in genomics, molecular biology and computing power has made it possible for the field of biotechnology to advance and develop more targeted medicines, manufacture high nutrition crops, and even manufacture grow artificial organs and tissues. Emerging markets like China, Brazil and India are leading the sales in the global biotechnology market. The Americas and Europe regions hold the biggest share in the global biotechnology industry - Americas had a share of nearly 45%, followed by Europe accounting for nearly 30% of the global biotechnology industry. The medical/healthcare segment is the leading segment of the biotechnology industry and in 2014 it consisted of nearly 60% of the global biotech industry's total value. This was followed by the food and agriculture segment. The research analyzes the Global Biotechnology Industry in this comprehensive research report. Analyzing the Global Biotechnology Industry covers the biotech market from the year 2010 till 2019. The report analyzes a total of 23 biotech markets and over 40 biotech companies. Key Topics Covered: A. Executive Summary B. Industry Definition C. Global Biotechnology Industry D. Global Biotechnology Industry: Porter's Five Forces Framework Analysis E. Blurring Differences between Biotech & Pharma Companies F. Global Biotechnology Industry: Market Trends & Challenges G. Global Biotechnology Industry: Analysis of Key Markets H. Global Biotechnology Industry: Major Players Companies Mentioned - AbbVie Inc. - Abbott Laboratories - Acorda Therapeutics Inc. - Actelion Ltd - Amgen, Inc. - Amylin Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Baxter International Inc. - Biocon Limited - Biogen Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CSL Limited - Celgene Corporation - Covance Inc. - Crucell N.V. - Cubist Pharmaceuticals - Daiichi Sankyo Co., Ltd. - Esteve Group - F. Hoffmann-La Roche AG - GE Healthcare - Gentium S.p.A. - Genzyme Corporation - Gilead Sciences, Inc. - Grifols SA - ImmunoGen, Inc. - Johnson & Johnson - Menarini Group - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - MorphoSys AG - Novartis AG For more information visit http://www.researchandmarkets.com/research/r6...lyzing_the
ACOR: 33.07 (+0.14), CVD: 106.42 (-0.71), JNJ: 92.93 (+0.21), ABBV: 59.35 (-0.23), ABT: 43.41 (+0.29), CBSTZ: 0.06 (unch), IMGN: 13.86 (+0.59), AMGN: 153.21 (+0.07), BMY: 59.22 (+0.47), GRFS: 32.15 (+0.40), GILD: 109.63 (+2.38), BAX: 36.02 (-0.05), AZN: 33.30 (+0.02), MRK: 52.09 (-0.63), NVS: 96.55 (+0.28), CELGZ: 1.93 (+0.07)
Osteoporosis Pipeline Review, H1 2015 - Reviews key players involved in the therapeutics development for Osteoporosis
M2 - Mon Aug 17, 8:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7r4gzx/osteoporosis) has announced the addition of the "Osteoporosis - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoporosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Abiogen Pharma S.p.A. - Ablynx NV - Alethia Biotherapeutics Inc. - Alize Pharma SAS - Alkem Laboratories Ltd. - Amgen Inc. - Amura Holdings Limited - Arcarios BV - Astellas Pharma Inc. - Bone Medical Limited - Bone Therapeutics SA - Caladrius Biosciences, Inc. - Chronos Therapeutics Limited - Chugai Pharmaceutical Co., Ltd. - Corium International, Inc. - Critical Pharmaceuticals Limited - Daiichi Sankyo Company, Limited - ElexoPharm GmbH - Eli Lilly and Company - EndoCeutics, Inc. - Ensoltek Co., Ltd. - Enzo Biochem, Inc. - F. Hoffmann-La Roche Ltd. - Galapagos NV - Glide Pharmaceutical Technologies Limited - Hanmi Pharmaceuticals, Co. Ltd. - Haoma Medica Ltd. - IMMD Inc. - Immunovo BV - Inbiopro Solutions Pvt. Ltd. - Kaken Pharmaceutical Co., Ltd. - Kolltan Pharmaceuticals, Inc. - Lead Discovery Center GmbH For more information visit http://www.researchandmarkets.com/research/7r...teoporosis
AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), CLBS: 1.97 (+0.01), GLPG: 59.00 (-0.06), CORI: 10.76 (+0.06), ENZ: 3.04 (-0.03)
Global Streptococcal Infections Active Pharmaceutical Ingredients (API) Insights 2015-2016
M2 - Mon Aug 17, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nzsv6x/streptococcal) has announced the addition of the "Streptococcal Infections-API Insights" report to their offering. Streptococcal Infections-API Insights, 2015 report provides Streptococcal Infections drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Streptococcal Infections. The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Streptococcal Infections drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2012-2016) - Marketed Drugs Information - Drugs Description - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Discontinued Drugs Information Companies Mentioned - Hospira, Inc. - Arbor Pharmaceuticals, Inc. - Pfizer Inc. - Abbott Laboratories - Astellas Pharma US, Inc. - Pharmacia & Upjohn, Inc. - Warner Chilcott Plc - Baxter Healthcare Corporation For more information visit http://www.researchandmarkets.com/research/nz...eptococcal
ABT: 43.41 (+0.29), PFE: 32.97 (+0.35)
Ovarian Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Ovarian Cancer
M2 - Mon Aug 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/752ksw/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. Summary This, Ovarian Cancer - Pipeline Review, H1 2015', provides an overview of the Ovarian Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: Overview Therapeutics Development Therapeutics under Development by Companies Therapeutics under Investigation by Universities/Institutes Pipeline Products Glance Products under Development by Companies Products under Investigation by Universities/Institutes Companies Involved in Therapeutics Development Therapeutics Assessment Drug Profiles Recent Pipeline Updates Dormant Projects Discontinued Products Product Development Milestones Companies Mentioned - 3-V Biosciences, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abeona Therapeutics, Inc. - AbGenomics International, Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advantagene, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Agilvax, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Amorfix Life Sciences Ltd. - Anavex Life Sciences Corp. - Angstrom Pharmaceuticals, Inc. - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aprea AB - arGEN-X BV - Armour Therapeutics Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. For more information visit http://www.researchandmarkets.com/research/75...ian_cancer
ADXS: 16.51 (+0.55), ADRO: 20.40 (+0.27), AMBX: (), AMGN: 153.21 (+0.07), ABEO: 5.48 (+0.17), AAAP: (), ABBV: 59.35 (-0.23), PMN.TO: 0.07 (-0.02), ARRY: 5.88 (-0.05), XLRN: 33.62 (+1.44)
Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015 - Summarizes all the dormant and discontinued pipeline projects
M2 - Mon Aug 17, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q7drg7/glioblastoma) has announced the addition of the "Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015" report to their offering. Summary This, Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2015', provides an overview of the Glioblastoma Multiforme (GBM)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects - A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - AB Science - AbbVie Inc. - Actelion Ltd - Actinium Pharmaceuticals, Inc. - Actinogen Limited - Activartis Biotech GmbH - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advanced Cancer Therapeutics - Advenchen Laboratories, LLC - Agenus, Inc. - AGY Therapeutics, Inc. - Amal Therapeutics SA - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AngioChem Inc. - Apogenix GmbH - Argon Pharma S.L. - Ariad Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Axelar AB - Bexion Pharmaceuticals, LLC. - biOasis Technologies Inc. - BioCancell Ltd - Biomar Microbial Technologies - Bioncotech Therapeutics S.L. - Biovista Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CalAsia Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/q7...ioblastoma
ATNM: 2.44 (+0.07), ADRO: 20.40 (+0.27), AMBX: (), AZN: 33.30 (+0.02), AMGN: 153.21 (+0.07), AMPE: 3.12 (+0.14), ABBV: 59.35 (-0.23), BMY: 59.22 (+0.47), AAAP: ()
Colorectal Cancer - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colorectal Cancer
M2 - Fri Aug 14, 5:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvsdxp/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Key Topics Covered: - Colorectal Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Angiogene Pharmaceuticals Limited - Antibe Therapeutics, Inc. - Aphios Corporation - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Bayer AG - Beta Cat Pharmaceuticals, LLC - Biocon Limited - Bionomics Limited - BioNovion B.V. - Biothera, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company For more information visit http://www.researchandmarkets.com/research/dv...tal_cancer
ADXS: 16.51 (+0.55), ARQL: 1.71 (-0.01), AMGN: 153.21 (+0.07), BMY: 59.22 (+0.47), ATNM: 2.44 (+0.07), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), ABBV: 59.35 (-0.23), ARRY: 5.88 (-0.05)
Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Multiple Myeloma (Kahler's Disease)
M2 - Fri Aug 14, 5:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjk4fl/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015" report to their offering. This, Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2015', provides an overview of the Multiple Myeloma (Kahler's Disease)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler's Disease) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Key Topics Covered: - Multiple Myeloma (Kahler's Disease) Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - 4SC AG - AB Science - AbbVie Inc. - Ablynx NV - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Actinium Pharmaceuticals, Inc. - Adaptimmune Limited - Advancell - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Amorfix Life Sciences Ltd. - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Aptose Biosciences Inc. - Arcarios BV - Arno Therapeutics, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Aurigene Discovery Technologies Limited - AVEO Pharmaceuticals, Inc. - AvidBiotics Corp. - Axelar AB - Bayer AG - BenovusBio LLC - Biogenomics Limited - BioInvent International AB - BioNovion B.V. - Biotest AG - Bluebird bio, Inc. For more information visit http://www.researchandmarkets.com/research/rj...le_myeloma
AMGN: 153.21 (+0.07), APTO: 5.05 (-0.02), ATNM: 2.44 (+0.07), ANTH: 8.03 (-0.15), AVEO: 1.36 (unch), ABBV: 59.35 (-0.23), PMN.TO: 0.07 (-0.02), XLRN: 33.62 (+1.44), ARRY: 5.88 (-0.05)
Schizophrenia - Pipeline Review, H1 2015
M2 - Fri Aug 14, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fjzmkc/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned Partial list of the 70 companies featured in the report: - Acadia Pharmaceuticals - Adamed Sp. - Aestus Therapeutics - AGY Therapeutics - Alkermes - Amgen - Angita - ANP Technologies - Ascendis Pharma - Astellas Pharma - Athersys - BCWorld Pharm - BioCrea - Biotie Therapies - Boehringer Ingelheim - Cerecor - Critical Pharmaceuticals - Curemark - Delpor - Domain Therapeutics - Dong Wha Pharma - Echo Pharmaceuticals - Egis Gyogyszergyar Nyrt - Eli Lilly and Company - Evotec - F. Hoffmann-La Roche - FORUM Pharmaceuticals - Galenea - GeNeuro - Genovate Biotechnology Full list available at http://www.researchandmarkets.com/research/fj...izophrenia
ACAD: 41.69 (+0.52), AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), ALKS: 70.95 (+1.28)
Hepatic Insufficiency Global Clinical Trials Review, H1 2015 - Clinical Trial Overview of Top Companies
M2 - Thu Aug 13, 6:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/927w44/hepatic) has announced the addition of the "Hepatic Insufficiency Global Clinical Trials Review, H1, 2015" report to their offering. Hepatic Insufficiency Global Clinical Trials Review, H1, 2015 Summary Our clinical trial report, Hepatic Insufficiency Global Clinical Trials Review, H1, 2015" provides data on the Hepatic Insufficiency clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatic Insufficiency. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatic Insufficiency. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Merck & Co., Inc. - Novartis AG - Eli Lilly and Company - Puma Biotechnology, Inc. - Johnson & Johnson - GlaxoSmithKline plc - C. H. Boehringer Sohn AG & Co. KG - Pfizer Inc. - Bristol-Myers Squibb Company - Astellas Pharma Europe Ltd. Clinical Trial Overview of Top Institutes / Government - Copenhagen University Hospital Gentofte - Clinical Trial Overview of Copenhagen University Hospital Gentofte - National Cancer Institute - Clinical Trial Overview of National Cancer Institute - Aarhus University - Clinical Trial Overview of Aarhus University - Donau-Universitat Krems - Clinical Trial Overview of Donau-Universitat Krems - Huashan Hospital - Clinical Trial Overview of Huashan Hospital - Mayo Clinic - Clinical Trial Overview of Mayo Clinic - McGill University Health Center For more information visit http://www.researchandmarkets.com/research/927w44/hepatic
JNJ: 92.93 (+0.21), PFE: 32.97 (+0.35), MRK: 52.09 (-0.63), LLY: 81.80 (+0.96), GSK: 40.26 (+0.02), BMY: 59.22 (+0.47), PBYI: 103.28 (+6.59), NVS: 96.55 (+0.28)
Respiratory Syncytial Virus (RSV) Infections: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fswgvd/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects Companies Mentioned - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AlphaVax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Artificial Cell Technologies, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Celltrion, Inc. - Codagenix, Inc. - Crucell N.V. - CureVac GmbH - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Humabs BioMed SA - iBio, Inc. - Immunovaccine, Inc. - Johnson & Johnson - Kineta, Inc. - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - Microbiotix, Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation For more information visit http://www.researchandmarkets.com/research/fs...espiratory
ADMA: 9.35 (+0.36), EBS: 32.58 (+0.39), BOTA: 2.08 (-0.08), GSK: 40.26 (+0.02), JNJ: 92.93 (+0.21), GILD: 109.63 (+2.38), MRK: 52.09 (-0.63), AZN: 33.30 (+0.02), IBIO: 0.70 (-0.01)
Diffuse Large B-Cell Lymphoma Pipeline Review, H1 2015 - Provides a Snapshot of the Global Therapeutic Landscape of Diffuse Large B-Cell Lymphoma
M2 - Thu Aug 13, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/drv9fj/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diffuse Large B-Cell Lymphoma and enlists all their major and minor projects Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Companies Mentioned - AbbVie Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BIND Therapeutics, Inc. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - CureTech Ltd. - Curis, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/dr...fuse_large
CRIS: 2.64 (-0.05), EPZM: 20.70 (+0.23), CTIC: 1.62 (+0.01), JNJ: 92.93 (+0.21), INFI: 8.82 (-0.05), ABBV: 59.35 (-0.23), CBMG: 22.85 (-0.01), IMMU: 2.22 (+0.01), INCY: 131.01 (+6.51), IMGN: 13.86 (+0.59), AMGN: 153.21 (+0.07), BIND: 5.05 (+0.13), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), IDRA: 3.34 (+0.26), GILD: 109.63 (+2.38), AZN: 33.30 (+0.02), CELGZ: 1.93 (+0.07)
